CD 38 is a multifunctional cell surface protein that has receptor as well as enzyme functions.
The protein is generally expressed at low levels on various hematological and solid tissues …

Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma
previously considered to have a poor prognosis. Large gains were made in the first decade …

PURPOSE Nivolumab was assessed in patients with virus-associated tumors in the phase
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …

Background Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab,
a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1–2 trial involving patients …

Background New treatment options are needed for patients with multiple myeloma that is
refractory to proteasome inhibitors and immunomodulatory drugs. We assessed …

Daratumumab is an anti-CD38 monoclonal antibody with lytic activity against multiple
myeloma (MM) cells, including ADCC (antibody-dependent cellular cytotoxicity) and CDC …

Multiple myeloma (MM) is a disease that affects plasma cells and can lead to devastating
clinical features such as anemia, lytic bone lesions, hypercalcemia, and renal disease. An …

Immunotherapeutic strategies are emerging as promising therapeutic approaches in
multiple myeloma (MM), with several monoclonal antibodies in advanced stages of clinical …

Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that
is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that …

Background Elotuzumab, an immunostimulatory monoclonal antibody targeting signalling
lymphocytic activation molecule (SLAM) family member 7 (SLAMF7), selectively kills …